Revenue growth on a constant currency basis was 10 percent after adjusting for a $145 million negative foreign currency translation.
Revenue outside the United States grew 6 percent to $1.5 billion compared to the same period last year, or 16 percent on a constant currency basis.
Cardiac rhythm disease management revenue grew nearly 3 percent to $1.3 billion; spinal revenue grew 7 percent to $915 million; cardio vascular revenue grew 9 percent to $689 million; and neuromodulation revenue grew 7 percent to $373 million.
Read the release on Medtronic’s first-quarter 2010 earnings.
